Login to Your Account



'TWIST' AND DOUBT

Valeant $45B Allergan bid clever, but will board go along?

By Randy Osborne
Staff Writer

Tuesday, April 22, 2014
As Tuesday wore on, skepticism gave way regarding success for the hostile try by Valeant Pharmaceuticals International Inc., with help from the hedge fund Pershing Square Capital Management L.P., to take over Allergan Inc. in a deal valued at about $45 billion. But the merger is by no means a deal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription